- Home
- ICLR vs BMRN Comparison
ICLR vs BMRN Comparison
Compare ICLR & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ICLR | BMRN |
|---|---|---|
| Founded | 1990 | 1996 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1B | 12.3B |
| IPO Year | 2001 | 1999 |
Fundamental Metrics
Financial Performance| Metric | ICLR | BMRN |
|---|---|---|
| Price | $168.38 | $55.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 28 |
| Target Price | ★ $185.88 | $91.59 |
| AVG Volume (30 Days) | 925.0K | ★ 2.1M |
| Earning Date | 10-27-2026 | 10-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.77 |
| Revenue | N/A | ★ $1,313,646,000.00 |
| Revenue This Year | N/A | $21.45 |
| Revenue Next Year | $3.63 | $14.55 |
| P/E Ratio | ★ $12.91 | $70.62 |
| Revenue Growth | N/A | ★ 17.62 |
| 52 Week Low | $66.57 | $49.26 |
| 52 Week High | $203.91 | $70.98 |
Technical Indicators
Market Signals| Indicator | ICLR | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 52.53 | 29.88 |
| Support Level | $162.32 | $53.53 |
| Resistance Level | $179.47 | $57.95 |
| Average True Range (ATR) | 6.91 | 1.36 |
| MACD | -0.15 | -0.34 |
| Stochastic Oscillator | 54.55 | 16.33 |
Price Performance
Historical ComparisonAbout ICLR ICON plc
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.